Elizabeth J. Rowe

Elizabeth J. Rowe

Auto-generated profile, based on publicly available information

Elizabeth J. Rowe

Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2021 in Clinical and Translational Science
Verified
Journal Article
Open access
PDF file
STSony Tuteja
Sony Tuteja
RSRamzi Salloum
Ramzi Salloum
AEAmanda Leigh Elchynski
Amanda Leigh Elchynski
DSD. Max Smith
D. Max Smith
ERElizabeth Rowe
Elizabeth Rowe
FGfor the IGNITE Pharmacogenetics Working Group
for the IGNITE Pharmacogenetics Working Group
There is growing interest in utilizing pharmacogenetic (PGx) testing to guide antidepressant use, but there is lack of clarity on how to implement testing into clinical practice. We administered two surveys at 17 sites that had implemented or were in the process of implementing PGx testing for antidepressants. Survey 1 collected data on the process and logistics of testing. Survey 2 asked sites to rank the importance of Consolidated Framework for Implementation Research (CFIR) constructs using best‐worst scaling choice experiments. Of the 17 sites, 13 had implemented testing and four were in the planning stage. Thirteen offered testing in the outpatient setting, and nine in both outpatient/inpatient settings. PGx tests were mainly ordered by psychiatry (92%) and primary care (69%) providers. CYP2C19 and CYP2D6 were the most commonly tested genes. The justification for antidepressants selected for PGx guidance was based on Clinical Pharmacogenetics Implementation Consortium guidelines (94%) and US Food and Drug Administration (FDA; 75.6%) guidance. Both institutional (53%) and commercial laboratories (53%) were used for testing. Sites varied on the methods for returning results to providers and patients. Sites were consistent in ranking CFIR constructs and identified patient needs/resources, leadership engagement, intervention knowledge/beliefs, evidence strength and quality, and the identification of champions as most important for implementation. Sites deployed similar implementation strategies and measured similar outcomes. The process of implementing PGx testing to guide antidepressant therapy varied across sites, but key drivers for successful implementation were similar and may help guide other institutions interested in providing PGx‐guided pharmacotherapy for antidepressant management.

1 May 2022 in JCO Precision Oncology
Verified
Journal Article
Closed access
TSTyler Shugg
Tyler Shugg
RLReynold C. Ly
Reynold C. Ly
ERElizabeth J. Rowe
Elizabeth J. Rowe
SPSantosh Philips
Santosh Philips
MHMustafa A. Hyder
Mustafa A. Hyder
TSTodd Skaar
Todd Skaar
PURPOSE: Precision medicine approaches, including germline pharmacogenetics (PGx) and management of drug-drug interactions (DDIs), are likely to benefit patients with advanced cancer who are frequently prescribed multiple concomitant medications to treat cancer and associated conditions. Our objective was to assess the potential opportunities for PGx and DDI management within a cohort of adults with advanced cancer.METHODS: Medication data were collected from the electronic health records for 481 subjects since their first cancer diagnosis. All subjects were genotyped for variants with clinically actionable recommendations in Clinical Pharmacogenetics Implementation Consortium guidelines for 13 pharmacogenes. DDIs were defined as concomitant prescription of strong inhibitors or inducers with sensitive substrates of the same drug-metabolizing enzyme and were assessed for six major cytochrome P450 (CYP) enzymes.RESULTS: Approximately 60% of subjects were prescribed at least one medication with Clinical Pharmacogenetics Implementation Consortium recommendations, and approximately 14% of subjects had an instance for actionable PGx, defined as a prescription for a drug in a subject with an actionable genotype. The overall subject-level prevalence of DDIs and serious DDIs were 50.3% and 34.8%, respectively. Serious DDIs were most common for CYP3A, CYP2D6, and CYP2C19, occurring in 24.9%, 16.8%, and 11.7% of subjects, respectively. When assessing PGx and DDIs together, approximately 40% of subjects had at least one opportunity for a precision medicine–based intervention and approximately 98% of subjects had an actionable phenotype for at least one CYP enzyme.CONCLUSION: Our findings demonstrate numerous clinical opportunities for germline PGx and DDI management in adults with advanced cancer.

17 November 2023 in Pharmacogenomics
Verified
Journal Article
Closed access
SSSarah A Shue
Sarah A Shue
ERElizabeth Rowe
Elizabeth Rowe
LBLauren A Bell
Lauren A Bell
TDTeresa Damush
Teresa Damush
ADAlexis DeLong
Alexis DeLong
DHDavid Haggstrom
David Haggstrom
Aim: To advance clinical adoption and implementation of pharmacogenomics (PGx) testing, barriers and facilitators to these efforts must be understood. This study identified and examined ba...

1 January 2026 in JCO Oncology Advances
Verified
Journal Article
Closed access
ERElizabeth J. Rowe
Elizabeth J. Rowe
NPNicholas R. Powell
Nicholas R. Powell
TSTodd Skaar
Todd Skaar
PURPOSE: Docetaxel-related toxicities can limit cancer treatment and be fatal. It is metabolized by the cytochrome P450 3A4 enzyme. We evaluated the association of rare reduced-function CYP3A4 variants with grade 3-4 docetaxel-induced toxicity. METHODS: We analyzed data from the SUCCESS-A breast cancer study available from the Database for Genotypes and Phenotypes. In our retrospective, case-control analysis of the data, 3,208 patients were enrolled in the original study, received docetaxel, and had genetic data and associated docetaxel-induced toxicity outcomes available. CYP3A4 genotypes were not originally determined for individuals in the SUCCESS-A study, so we imputed CYP3A4 genotypes using the TOPMed imputation server. The development of grade 3-4 docetaxel-induced hematological toxicities in patients with two copies of the reduced-function CYP3A4*22 allele were compared with those with normal function alleles. RESULTS: Eight individuals had imputed CYP3A4*22 / *22 genotypes. Six of them (75%) experienced grade 3-4 toxicities. In comparison, 56% of the CYP3A4*1 / *1 (normal function alleles) participants (n = 1,628; P = .31, odds ratio [OR], 2.41 [95% CI, 0.43 to 24.49) and 50.9% (n = 145) of the CYP3A4*1 / *22 participants developed grade 3-4 toxicities ( P = .11, OR, 1.23 [95% CI, 0.96 to 1.58]). CONCLUSION: Although not statistically significant, patients with the rare CYP3A4*22 / *22 genotypes may be at increased risks of severe toxicities.